Comment on CMS-2026-2212-0001

Summary: McKesson Corporation, a global healthcare supply chain leader, argues that CMS should adopt a narrow definition of "PBM" and "affiliate" for the implementation of Section 6224 of the CAA. They contend that the regulations should only apply to entities that exercise substantive decision-making authority over Part D drug benefits on behalf of PDP sponsors, specifically excluding pharmaceutical wholesalers and other supply chain participants who do not perform these core functions.